Results 91 to 100 of about 299,295 (343)

IMMUNO-CORRECTING THERAPY AND INCREASED NITRATE EFFECTIVENESS IN ANGINA TREATMENT

open access: yesРоссийский кардиологический журнал, 2010
The justification of this study is the need for new methods (potentially, immuno-correcting therapy) of increasing nitrate effectiveness in complex angina treatment, reducing nitrate adverse effect incidence, and minimizing nitrate contraindications.
V. V. Anikin   +2 more
doaj  

Developing a Machine Learning Model to Predict 180-day Readmission for Elderly Patients with Angina

open access: yesReviews in Cardiovascular Medicine
Background: Readmission of elderly angina patients has become a serious problem, with a dearth of available prediction tools for readmission assessment. The objective of this study was to develop a machine learning (ML) model that can predict 180-day all-
Yi Luo, Xuewu Song, Rongsheng Tong
doaj   +1 more source

Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization: Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial

open access: yesCirculation, 2016
Background— Angina often persists or returns in populations following percutaneous coronary intervention (PCI). We hypothesized that ranolazine would be effective in reducing angina and improving quality of life (QOL) in incomplete revascularization (ICR)
Karen P. Alexander   +13 more
semanticscholar   +1 more source

Improved risk stratification in unstable angina: Identification of patients at low risk for in‐hospital cardiac events by admission echocardiography [PDF]

open access: bronze, 1998
James H. Stein   +6 more
openalex   +1 more source

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 998-1012, April 2025.
In patients with Acute Myocardial Infarction related heart failure, the in‐hospital administration of ARNIs was associated with a reduced risk of MACEs and re‐hospitalizations for heart failure, as well as cardiac remodeling, compared to standard therapy.
Gianluca Di Pietro   +15 more
wiley   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Patients With Nonobstructive Coronary Artery Disease and Chest Pain: Impact of Obesity and Depressive Symptoms

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Chest pain (CP) in patients with nonobstructive coronary artery disease is a therapeutic challenge affecting morbidity and mortality. We aimed to identify clinical factors associated with CP in this population, hypothesizing that obesity and ...
Nishant Vatsa   +14 more
doaj   +1 more source

Nonlinear association of triglyceride‐glucose body mass index with all‐cause mortality in postmenopausal women, a retrospective cohort study: Evidence from the 2001 to 2014 National Health and nutrition examination survey

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Background The triglyceride‐glucose body mass index (TyG‐BMI) is a novel indicator combining an insulin resistance proxy (TyG index) with adiposity. It remains unclear how TyG‐BMI relates to long‐term mortality risk in postmenopausal women, a group prone to metabolic changes after menopause.
Xiliang Wang   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy